The RCS analysis showed that the risk of discontinued NAT in gastric cancer patients receiving NAT plus gastrectomy was relatively stable before the age of 55, but started to increase from 55 years, reaching the peak around 74 years old. This evidence concerns the gene BRD2 and gastric cancer.